Elbasvir/grazoprevir/uprifosbuvir

Drug Profile

Elbasvir/grazoprevir/uprifosbuvir

Alternative Names: Elbasvir/grazoprevir/MK-3682; MK 3682/MK 8742/MK 5172; MK-3682A

Latest Information Update: 20 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antivirals; Macrocyclic compounds; Small molecules; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 06 May 2016 Discontinued - Phase-II for Hepatitis C (PO) (Merck pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top